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Highlights 
 Validation of a self declared MS Population with a clinically diagnosed one. 
 We analysed the UK  MS Register for a number of key characteristics. The internet 
(n=11,021) and clinical (n=3,003) populations were studied for key shared 
epidemiology. We found them to be closely matched for mean age at diagnosis 
(clinical=37.39, portal=39.28) and gender ratio (female %, portal=73.1, clinical=75.2) 
 There is a representative population of people with MS in the online element of the 
UK MS – The MS Register can be treated as a valid instrument for Clinical and PRO 
research  
 Kernel Density of the populations for Age can be seen below: 
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ABSTRACT 
The UK Multiple Sclerosis Register (UKMSR) is a large cohort study designed to capture ‘real 
world’ information about living with multiple sclerosis (MS) in the UK from diverse sources. 
The primary source of data is directly from people with Multiple Sclerosis (pwMS) captured 
by longitudinal questionnaires via an internet portal. This population’s diagnosis of MS is 
self-reported and therefore unverified.  The second data source is clinical data which is 
captured from MS Specialist Treatment centres across the UK. This includes a clinically 
confirmed diagnosis of MS (by Macdonald criteria) for consented patients.  
 
A proportion of the internet population have also been consented at their hospital making 
comparisons possible. This dataset is called the ‘linked dataset’.  The purpose of this paper is 
to examine the characteristics of the three datasets: the self-reported portal data, clinical 
data and linked data, in order to assess the validity of the self-reported portal data. 
 
The internet (n=11,021) and clinical (n=3,003) populations were studied for key shared 
characteristics. We found them to be closely matched for mean age at diagnosis 
(clinical=37.39, portal=39.28) and gender ratio (female %, portal=73.1, clinical=75.2). The 
Two Sample Kolmogorov-Smirnov test was for the continuous variables to examine is they 
were drawn from the same distribution. The null hypothesis was rejected only for age at 
diagnosis (D = 0.078, p < 0.01). The populations therefore, were drawn from different 
distributions, as there are more patients with relapsing disease in the clinical cohort. In all 
other analyses performed, the populations were shown to be drawn from the same 
distribution. 
 
Our analysis has shown that the UKMSR portal population is highly analogous to the entirely 
clinical (validated) population. This supports the validity of the self-reported diagnosis and 
therefore that the portal population can be utilised as a viable and valid cohort of people 
with Multiple Sclerosis for study. 
 
Keywords: Multiple Sclerosis, data linkage, longitudinal, research register, 
validation, PROMs 
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1. Introduction  
Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the 
central nervous system (CNS), and the most common non-traumatic cause of disability in 
young adults worldwide (1). The dominant phenotype is characterised by relapses (attacks) 
and remissions - relapsing MS (RRMS). This evolves at 10-15 years into secondary 
progressive MS (SPMS) in the majority of those affected. About 15% of people with MS 
(PwMS) develop progressive neurological dysfunction from onset – primary progressive MS 
(PPMS).(2)  
 
The disease affects about 120,000 people in the United Kingdom (UK) with an incidence that 
appears to be increasing by approximately 2.5% per annum (4). There is a notably significant 
societal and global burden of £3bn/year (3) 
 
In order to comprehensively map the prevalence and characteristics of MS across the UK, 
the MS Society commissioned Swansea University Medical School, home to the Secure 
Anonymous Information Linkage (SAIL) Databank (4), to develop the UK Multiple Sclerosis 
Register (UKMSR). The SAIL databank is a safe haven for billions of person-based records 
combined with a complete data linkage and an analysis toolset. The knowledge and 
resources used to operate and maintain this SAIL were instrumental in the development of 
the UKMSR 
 
Data  to be captured were established during a setup and pilot phase of 36 months 
following a review of data captured by a number of European Registries (5) and reference to 
UK Neurologists, research academics and PwMS. The ‘real world’ data for the UKMSR would 
be captured from three primary sources: 
 
1) Data provided by PwMS via the internet (portal data). 
2) Data from NHS hospitals (clinical data). 
3) Data mined from general practice and inpatient hospital records (routine 
data). 
 
The Register has a mandated minimum clinical dataset [Appendix 2] which was developed 
by its Clinical Advisory Group (CAG) of UK neurologists. This pragmatic dataset, which is 
collected annually, following patient consent. Contains both demographic and clinical 
variables. Clinical data are then linked with portal data. Linkage occurs either when the 
participant enters their Study ID, or through deterministic and probabilistic methodologies 
(6). This route was chosen as there are known, notable limitations in finding MS patients in 
inpatient, outpatient and General Practice data. Secondary care routinely capture patient 
events by ICD10 codes ( G35-G37) as “Demyelinating disease of the Central Nervous 
System” (7) and general practitioner systems a READ code as “Multiple Sclerosis”(F20) (8).  
With no finer grained detail as to disease type available, this makes the minimum dataset 
capture of MS Specialist treatment centre data an essential part of the validation process. 
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Other studies using solely participant supplied data such as the North American Research 
Committee on Multiple Sclerosis (NARCOMS) were successful in validating their populations 
by carrying out expert review on a sample of their population. A selection of participants 
were consented, their medical records requested and treating physicians interviewed. The 
observed eligible population for this validation exercise was 142 participants out of 30,691, 
this further reducing to 52 consenting to participate.(9). Despite some caveats, NARCOMS 
reported the diagnostic accuracy of their population as being 98.7±1.3% in 2006. Since 
UKMSR portal participant’s self-reported data can be validated with their clinically collected 
data, there was no need to contact clinicians or review patient notes as clinical data is 
transmitted from source.  
 
2. Methods  
2.1 Study design and participants  
 
The UKMSR has two main sources of data: Patient Reported Outcome Measures (PROMs) 
and demographics supplied via the web portal and secondly consented patients ‘clinical 
data’ from MS Specialist Treatment centres across the UK. Participants on both platforms 
are encouraged to join the other where possible. That is PwMS who give informed consent 
for the transmission of their clinical data are encouraged to also sign up to the portal and 
portal patients who are treated at an NHS partner site are encouraged to give their consent.  
  
This ultimately creates three data sets for analysis, the portal, the clinical and the linked 
population that exist in both primary sources [Figure 1].  
 
  
Figure 1- Venn diagram showing the linked population as an intersection of the internet participants with consented patients 
from a clinical site.   
 
The purpose of this paper is to examine the characteristics of these datasets in order to 
assess the validity of the self-reported portal data 
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2.11 Portal participants 
Portal participants must be aged 18 years or older and resident within the UK,  they agree to 
a terms of service (10) stating the Register’s responsibility for the use and storage of their 
data. PROMs are then presented in order to obtain demographics and other MS specific 
data. Participants then receive three monthly reminders requesting they return to complete 
new instruments. Initial PROMs include the Hospital Anxiety and Depression Scale (HADS) 
(11), EurQol Quality of Life (EQ-5D-3L) (12) and the Multiple Sclerosis Impact Scale 
(MSIS29v2) (13) Up to five years of longitudinal data for some participants have now been 
captured.  
 
2.12 Clinical participants 
Eligibility criteria for consent via an NHS Clinic requires that patients are aged over 18, 
resident in the UK and have a diagnosis of MS from a neurologist according to the McDonald 
Criteria (14). The UKMSR has been approved as a study by the South West Central Bristol 
Research Ethics Council, initially under registration code 11/SW/0160. Approval was 
renewed after five years under registration code 16/SW/0194. Consent is usually followed 
by collection of the minimum dataset [appendix 2]. This dataset comprises demography, 
disease history and course, symptoms, relapses and progression (if any), current and 
previous disease modifying therapies and two measures of function; a timed walk and 
clinician supplied EDSS score.  
   
Participating clinical sites [Appendix 1] are self-selecting, based on an application to the 
UKMSR directly, patient consent is taken, and data capture begins. Data are transmitted to 
the UKMSR using encrypted secure transfer methods, only electronic data are accepted, and 
uploads are carried out by sites monthly.  
 
2.13 Linked participants 
 
Consented patients receive a unique study ID, which they are asked to enter onto the portal 
to link their data.  Although probabilistic matching could be used to link patients between 
their clinical and portal data, only exact matches using the individually assigned study ID 
were used for this paper. Probabilistic matching relies on ‘fuzzy’ logic that build up a degree 
of confidence in the match, giving a probability or likelihood of match. This requires more 
than one variable between datasets, normally name, postcode, gender and date of birth. A 
score is assigned to each match, ranking the chance that it is a true match. Matches above a 
certain level of confidence, i.e. >95 % can then be used for the linkage. Deterministic 
matching, which requires an exact match between fields is the most exact method and was 
used for this study. 
 
 
2.2 Data   
All data were stored on a Microsoft SQL Server 2014 Database and Structured Query 
Language (SQL) queries were made to identify data for initial analysis, data cleansing and 
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aggregation, prior to statistical analysis. Analysis was conducted using the R statistical 
computing programming language (15) in the RStudio environment. 
 
Simple descriptive statistics were used to compare the portal and clinical datasets: mean 
(standard deviation) for continuous data and frequency tables for categorical data on key 
demographic markers. A Two-Sample Kolmogorov-Smirnov (K-S) test was then implemented 
using age at diagnosis and current age. This is a non-parametric statistical test which 
determines if two different continuous variables are from the same distribution. 
2.21 Portal Data  
In 2012, Jones et al described the portal population (16) as having  unique 7,279 participants 
by March 2017 this number has almost doubled to 14,720. After removing deceased, left 
study, obvious input errors (such as diagnosis in 1927) or those with incomplete eligible 
data, the number of records was reduced to 11,021. 
2.22 Clinical Data  
Clinical data is submitted to the UKMSR via clinical system or by eCRF: 
 8 Sites use the iMed MS Clinical System   
 2 Sites utilise another dedicated MS Clinical System  
 14 return an Electronic Case Return Form (eCRF)  
 
At the time of analysis, iMed sites had submitted 2,306 patients, of these 163 had missing or 
invalid data, leaving 2,143 valid records.  For the eCRF sites 888 records were submitted, 
when tested against the same criteria as for iMed 860 remained, leaving a combined total of 
3,003. [Figure 2]  
 
As of March 2017, there were 6,092 clinical informed consents, not all consented patients 
proceed online to provide data – only 4,053 of these consented individuals even provided 
an email address.  
2.23 Linked   
Deterministic matching required patients to exist in the portal and clinical datasets by study 
ID.  For the 860 eCRF records 9 were missing variables leaving 851 valid records. For iMed - 
2,705 records were checked using the same criteria leaving 1,776 (929 removed). For the 
portal, of the 11,021 entries checked for study ID with 9,619 removed, leaving 1402 records 
for analysis. Once linkage was made (allowing for nulls and incorrect values in diagnosis) 
there were 676 eligible records in both the clinical and portal data.  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Figure 2: Consort diagram showing data selection criteria 
 
 
3. Results  
Data from the three sources: Portal, Clinical and Linked were compared and analysed.  
3.1 Demographic Details 
 
A total of 11,021 participants were included in this study 8,052 female and 2969 males (F:M  
2.7:1). This population was subdivided between clinical and linked and more complete 
demography is described in Table 1.  
 
 Clinical  Portal  Linked  
  n=3,003  n=11,021  n=676  
Age (mean) 48.8 ± 11.9  52.3 ± 11.7  48.3 ±11.3  
Age at diagnosis 37.4 ± 10.6  39.3 ± 10.2  38.6 ± 10.6  
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Gender (female) 2,178 (75.2%)  8,052 (73.1%)  493 (72.9%)  
PPMS 198 (6.5%)  1,514 (13.7%)  51(7.5%)  
RRMS 2,564 (85.3)  7,408 (67.2%)  567(83.8%)  
SPMS 122 (4.0%)  839 (7.6%)  21(3.1%)  
Other 119(3.9%)  1,260 (11.4%)  37(5.4%)  
Table 1: UKMSR datasets compared by age, age at diagnosis and MS Type at diagnosis  
 
Mean age at entry to the study for the portal population was 52.3 years (SD 11.9), for the 
purely clinical population 48.8 (SD 48.8) and for the linked set 48.3 (SD 11.3). Mean age at 
diagnosis for the clinical population 37.4 (SD 37.4) and the portal 39.3 (SD 39.3), the 
overlapping linked population having a mean of 38.6 (SD 10.6). At time of capture the 85.3% 
of the clinical population were recorded as having RRMS, the portal reported 67.2% as 
RRMS and the linked as 83.8%. 10.5% of the clinical population were diagnosed with a 
progressive form of the disease with 21.3% of the portal indicating the same. 10.6% of the 
linked participants had progressive MS. 
 
Table 2 shows a more complete breakdown of the reported MS Types by gender and data 
source.  
 
  Total Linked Female %  Total Portal  Female%  Total Clinical  Female %  
PPMS 50  52%  1514  52.4%  198  48.4%  
RRMS 567  74.8%  7408  77.7%  2,521  74.6%  
SPMS 21  76.2%  839  66.3%  122  66.3%  
Other 37  72.9%  1260  74.4%  162  73.4%  
Table 2:  Gender distribution across the UKMSR 
 
For distributions of gender by disease type. Females show in higher proportions than males 
across all disease types except PPMS.  In the linked population 52% of PPMS are female, in 
the Portal 52.4% with only the male clinical population deviating from this trend at 51.6%. 
3.1.2 Location 
The location of UKMSR participants against the UK as a whole was carried out using Register 
and ONS data. English data matched most closely with the portal and clinical populations 
75.63% of the entire portal population being resident in an English Lower Super Output 
area. Northern Irish and Welsh participants being over represented at 12.36% and 12.01% 
respectively.  [Table 3].  The UKMSR currently has no clinical sites within Scotland.  
 
  
Country  
UKMSR Portal % 
population  
UKMSR Clinical 
population % 
Entire UK population (17) 
% 
England 77.6  75.63  84.2  
Northern Ireland 4.3  12.36  2.8  
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Wales 7.7  12.01  4.7  
Scotland 10.43 0  8.2  
 Table 3: UKMSR population distribution compared to the UK general population 
3.2 Validity of the data 
Comparing the ages of both the portal and clinical data using the two-sample K-S test 
revealed the populations were for the most part drawn from different distributions. The null 
hypothesis was rejected in the comparison of the datasets for both the current ages (D = 
0.131, p << 0.01) and the ages at diagnosis (D = 0.078, p << 0.01). As the D statistic is small, 
the overall difference in the age distributions is minimal [Figures 3 and 4]. When stratifying 
by age and RRMS disease type alone, the null hypothesis is still rejected, but by a much 
smaller margin (D = 0.131, p < 0.01). Figure 3 shows the overall kernel density of the UKMSR 
clinical and portal populations for age at diagnosis, with Figure 4 highlighting the same data 
for people with relapsing remitting disease.  
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Figure 3 Kernel density of age at diagnosis, Portal and Clinical Population 
 
Figure 3 Kernel density of current age at diagnosis, Portal and Clinical Population for people with RRMS 
 
Both the clinical and linked data show RRMS at diagnosis as >70% with the portal population 
at 67% being only slightly under this threshold.  There are small differences between the 
populations declaring SPMS, ‘Other’ and PPMS as observed on the portal. 
 
3.3 Quality of Self-Reported Data   
 
Table 4 shows those data supplied by linked participants, compared to their clinical data. 
There are 99% accuracy in matches for gender and date of birth. The 1% likely to be 
transcription errors.  Over 80% of clinicians and PwMS agree on the type of MS at diagnosis.  
62% of participants remember the year of diagnosis exactly and this percentage rises to 
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81.7% when a 1-year margin of error is allowed. For a population that have a mean of 13 
years since diagnosis this is statistically insignificant. 
  
Fields – Linked Clinical / Portal Count  %  
Total Linked Records  667  100  
Matched Gender   664  99.55  
Matching Date of Birth  652  97.7  
Matched Year of Diagnosis  430  64.47  
Date supplied within 1 year of Clinician Diagnosis 116  17.39  
Date supplied within 2 years of Clinician Diagnosis 37  5.55  
Date supplied within 3 years of Clinician Diagnosis 20  3.00  
Date more than 3 years of clinical diagnosis date  37  5.55  
Errors in Diagnosis Date  27  4.05  
MS Type given exact match with current MS Type from clinician  549  82.31  
 Table 4: Quality of self-reported variables against clinically reported data. 
4. Discussion   
 
The objective of this study was to assess if the online element of the MS Register could be 
treated as a valid cohort of people with MS in the absence of supporting clinical validation. 
The data presented above, particularly the similarities in portal and clinical data (D = 0.078, 
p << 0.01) supports this assumption, and will allow researchers to work with Register data 
sets with more confidence than was previously possible. It has however become clear 
during this analysis that there are more patients with relapsing remitting disease in the 
clinical data set than has been seen in other studies (Clinical 85.3%, Portal 67.2%). Previous 
MS registry studies (18), (19) the LORSEP Registry (17) and the Atlas of MS (20) have also 
indicated an RRMS population of more than 80% in newly diagnosed patients. This is clearly 
in agreement with the large proportion of RRMS diagnosed patients coming to the UK MS 
Register from our clinical sites. In 2015 the Neuroinflammatory service in Cardiff defined 
their PPMS cohort as being 11% of their total population (21). In the MS Clinical data, 
progressive data combined has a total of 10.4% and supports the skew to RRMS further.   
 
All other data are consistent with previous studies, there are more males with PPMS (22) 
but more females with other disease types. (23). The clinical group is on average 10 years 
younger than the portal - though well within the standard deviation, MS is a disease that is 
classically diagnosed in the mid to late 30’s (24) and the date of diagnosis for both clinical 
and portal are within 0.07% of each other.  Age at diagnosis of the portal population aligns 
well with other studies. (25), (19). One advantage to having a younger population overall  is 
that they are more likely to make use of the internet to  carry out PRO reporting (26).  
Internet usage is decreased in chronic disease (27) though overall UK Internet use amongst 
all age groups is increasing (17) with only 10.2% of the population never having accessed the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Internet. This may account for some of the disparity in the linked figures, but overall makes 
the collection of data using this methodology useful. 
 
An interesting aspect of the analysis was the comparison of the linked cohort’s responses 
against their clinical data with 81.7 % of patients remembering their diagnosis date to within 
1 year of accuracy. This strongly indicates that participants are reliable narrators of their 
disease which is essential for the utility and validity of the other PROMs in the MS Register.  
 
The capture of ‘real world’ / observational data rather than specific trial level data clearly 
brings with it a number of issues not typically seen in other cohort studies. The design of the 
UKMSR was to work with existing NHS clinical systems  primarily to validate participants 
diagnoses whilst being  mindful of the extra demands that data collections could have on 
busy NHS Staff (28).   
 
Limitations 
 
Other notable limitations include, the sample size of the linked population and the data 
quality of some captured variables from all sources – perhaps to be expected given the 
opportunistic capture methodology. The lack of clinical data from Scotland, is unfortunate 
but explained by the presence of the Scottish MS Register (16). These issues are all being 
addressed with more validation required by clinical sites submitting data. More stringent 
requirements for the self-entered data fields via the portal have been set. 
 
The MS Register only captures age at confirmed diagnosis, rather than age at onset as this is 
a date that is more readily available within clinical records. The definition varied in the 
literature and in some other studies (29), (30) but it is a variable that could be added to the 
clinical minimum dataset. Age at onset is however captured from participants via the portal. 
 
The recruitment of ‘self-declared’ people with MS via the internet is an inherent limitation, 
due to selection bias. This is slightly balanced by having ‘general’ recruitment at a variety of 
neurology centres across the UK – with the caveats about increased numbers of RRMS 
noted. To provide more balance to this, the UKMSR is now attempting to recruit more 
community care NHS Trusts and to encourage exiting sites to make more use of the postal 
consent methodology to capture those patients that may no longer attend clinics.  
5. Conclusions and future work 
 
This validation work demonstrates that in comparison to a clinical population there is 
representative sample emerging in the online portal population. This paper is a firm first 
step in being able to treat the online cohort of people with MS as a valid one and underpins 
the outcomes-based research that has already been carried out via the UKMSR.  
 
For the future the UKMSR will improve the quality and quantity of data collected from 
clinical systems and the internet by tightening the validation requirements of data entry. 
More linked data sets will be sought in order to increase data linkage and overall data 
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quality.  A potential example of this would be by comparison with another well 
characterised prevalent population, such as the Scottish incidence register.   
 
Clinically, capture of data will be improved from the NHS by transitioning to a new eCRF 
system that is easier to access from within the NHS and provides instant feedback on 
collected clinical data. Similar improvements on the portal collection methodology are 
planned and new methods of data capture will be provisioned, such as smartphone apps to 
collect participant activity data as a potentially concordant outcome measure with EDSS (31) 
.   
 
Around 30% of patients on average recruited via clinical sites that then go on to use UKMSR 
online. We therefore need to recruit more patients clinically, but also from sources more 
varied than secondary care specialist treatment centres, perhaps extending to more 
community trusts and rehabilitation teams.  Additionally, we are examining the application 
of Natural Language Processing techniques as a data capture methodology.  
 
The methodology of data capture from the internet, clinical systems and routine data has 
proven to be useful and crucially it is patient centred. Having established the validity of the 
cohort it becomes possible to make use of this research in a variety of ways. The first will be 
selecting subsets of the cohort that may be appropriate for clinical trials and making sure 
the broader dataset is fit for purpose. Of additional interest will be testing the whole cohort 
with novel online outcome measures that would be difficult to test on less well-
characterised or smaller clinical cohorts. For example, how a web-based participant supplied 
EDSS score compares to a formal clinically supplied one.  
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Appendix 1 
 
List of clinical sites that contributed data to this study  
 
 
ABMU NHS Trust Morriston Hospital 
Nottingham Hospitals NHS Trust, Queens Medical Centre 
UCL London Hospitals NHS Trust National Hospital for Neurology and Neurosurgery 
Belfast Health and Social Care Trust, Belfast City Hospital 
Barts Health NHS Trust, Royal London Hospital 
Shrewsbury and Telford NHS Trust, Royal Shrewsbury Hospital 
Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon Hospital 
 University Hospital Southampton NHS Foundation Trust. Southampton General Hospital 
 Oxford University Hospitals NHS Foundation Trust  John Radcliffe Hospital 
Poole Hospital NHS Foundation Trust, Poole Hospital 
 Brighton and Sussex University Hospitals NHS Trust , Princess Royal Hospital 
Royal Free London NHS Foundation Trust, Royal Free Hospital 
 Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital 
Salford Royal NHS Foundation Trust, Salford Royal Hospital 
Northampton NHS Trust, Northampton General Hospital 
 Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital  
Luton and Dunstable Hospital NHS Foundation Trust, Luton Hospital  
Frimley Park NHS Foundation Trust, Frimley Park Hospital  
Barking, Havering And Redbridge Hospitals NHS Trust, Queens Hospital  
Mid Yorkshire Hospitals NHS Trust, Pinderfields General Hospital 
Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospitals NHS Trust 
Southend University Hospital NHS Foundation Trust, Southend Hospital  
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Appendix 2 UK MS Register Minimum Dataset 
IP CAG 
 
UK	MS	Register	MDS	23/08/17
	Lack	of	efficacy	/	Side	Effects	/	Other
Patient	is:	(tick)
Natalizumab
Alemtuzumab Avonex
					Name	&	Address
Date /						/ Study	ID
/						/Date	StartedPAST	Disease	modifying	Treatment	(circle)
Conversion	to	SP
(if	applicable)
No.	of	Relapses	(RR	only)
(since	last	visit/year)
SevereModerateMild
Severity:
(circle)
Date	Stopped /						/ Reason	(circle)
		Current	EDSS	Score	(1-10)
Mitoxantrone
Natalizumab Ocrelizumab
Alemtuzumab FingolimodAvonex Betaferon Copaxone Extavia
Rebif Tecfidera
Person	completing	form: _______________________________________
Minimum	
Data	Set
Version	6.3
Time	=		___________
M	=			___________
/						/Date	EDSS	Taken
TIER	ONE	(all	fields	to	be	completed)
TIER	TWO	(to	be	completed	IF	patient	is	unlikely	to	register	online)
Pregnant Y N
		Onset	Localisation	(circle)
Spinal
No.	Per	Day Coordination Bowel/Bladder Fatigue
Trundle	wheelSelf-estimated
Walking	range	:	time	and	
distance	in	meters
Treadmill
Visual
Cortex
Smoked	since: Cognitive Encephalopathy Other
Sensory
Cerebellar/brainstem
Smoker Y N
	Onset	Symptoms	(circle)
Vision Motor
	PRESENT	Disease	modifying	Treatment	(circle) Date	Started
RR										SP								PP							Other
MS	Type	now MS	Type	at	Diagnosis
RR										SP								PP							Other
Date	of	onset
Date	of	Diagnosis
/										/										/
/								/					
Teriflunomide None
Ocrelizumab Rebif Tecfidera Teriflunomide
MitoxantroneFingolimodExtaviaCopaxoneBetaferon
None
/						/
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